Ben Parry
B.Sc. Engineering
Director
Ben is a Director based in Toronto and a trusted advisor to executive leadership teams with more than 20 years of experience helping healthcare organizations build, commercialize, and transform businesses in Canada. He has supported the successful commercialization of more than 20 pharmaceutical companies and products across pharmaceuticals and medical devices. Recognized for combining strategic vision with operational execution, Ben advises executives on market entry, commercialization strategy, channel optimization, and enterprise transformation to accelerate growth, strengthen competitive advantage, and deliver sustainable business value.
Ben is recognized for helping organizations navigate the complexity of the Canadian healthcare ecosystem by aligning commercial strategy, trade and channel partnerships, regulatory considerations, and operational excellence. His additional expertise spans enterprise demand planning, integrated trade development, supply chain optimization, financial risk management, and advanced business intelligence, data and analytics. By transforming complex data into actionable executive insight, he enables leadership teams to make better decisions, unlock working capital, optimize commercial performance, and build resilient organizations positioned for long-term success.
Prior to Pangaea, Ben managed the wholesale pharmaceutical portfolio at Kohl & Frisch Limited. He built trusted partnerships with Canada’s leading pharmaceutical manufacturers, wholesalers, distributors, and pharmacy organizations while developing trade frameworks, business intelligence platforms, continuity strategies, and supply chain capabilities. As a trusted advisor to executive leadership teams, Ben mentors senior leaders while shaping commercial strategy, organizational transformation, and market growth across Canada’s healthcare sector. He is recognized for bringing stakeholders together to solve complex commercial challenges and establish high-performing pharmaceutical businesses in one of the world’s most highly regulated healthcare markets.
Ben is a graduate of Queen’s University holding a B.Sc. in Engineering. Before joining the healthcare industry, Ben held engagements in manufacturing and R&D as well as capital markets.
Areas of expertise
- Business Strategy
- Trade Strategy
- Corporate Strategy
Recent articles by Ben Parry
Pangaea Express: New Implications to off-patent versions of a patented drug
January 31, 2024
Navigating while innovating: Considerations for launching in a risk-averse environment
August 21, 2020
Cross Border Sales of Prescription Drugs
April 26, 2019
Pangaea Express: McKesson acquires Rexall Health from Katz Group for $3B CAD
March 21, 2016
